Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 10/20 | 0.60 |
| ▸ | JAK2 | O60674 | 9/20 | 0.60 |
| ▸ | JAK1 | P23458 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13689999 | 0.90 | TYK2 (0.56) | TYK2JAK2JAK1SMN1; SMN2CYP3A4 | |
| SCHEMBL8278422 | 0.86 | MAPT (0.63) | TYK2JAK2SMN1; SMN2KMT2A | |
| SCHEMBL13602308 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2KMT2A | |
| SCHEMBL8278418 | 0.81 | NPC1 (0.71) | SMN1; SMN2KMT2A | |
| SCHEMBL13058075 | 0.81 | TYK2 (0.61) | TYK2JAK2JAK1SMN1; SMN2CYP3A4 | |
| SCHEMBL17538444 | 0.79 | CYP1A2 (0.62) | SMN1; SMN2KMT2A | |
| SCHEMBL7384072 | 0.77 | TYK2 (0.65) | TYK2JAK2JAK1SMN1; SMN2CYP3A4 | |
| SCHEMBL15779338 | 0.77 | NPC1 (0.65) | TYK2JAK2JAK1SMN1; SMN2CYP3A4 | |
| SCHEMBL14265186 | 0.76 | MAPT (0.49) | SMN1; SMN2TAS1R3TAS1R1KMT2A | |
| SCHEMBL3514474 | 0.76 | TYK2 (1.00) | TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2005113003-A2 | METHOD FOR AUGMENTING B CELL DEPLETION | GENENTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | TYK2 249/4885JAK2 127/4885JAK1 214/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | TYK2 1755/4885JAK2 1231/4885JAK1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.